Best Practice & Research Clinical Rheumatology
Volume 21, Issue 1 , Pages 109-122 , February 2007

Osteoporosis: strategies for prevention and management

  • Richard Keen, BSc, PhD, MRCP (Consultant Rheumatologist and Honorary Senior Lecturer in Metabolic Bone Disease)

      Affiliations

    • Corresponding Author InformationTel.: +44 20 8090 5289; Fax: +44 20 8420 7487.

References 

  1. World Health Organization Study Group . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series No. 843 Geneva: World Health Organization; 1994;
  2. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;29:517–522
  3. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010–2018
  4. Roy DK, O'Neill TW, Finn JD, et al. Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International. 2003;14(1):19–26
  5. O'Neill TW, Cooper C, Finn JD, et al. Incidence of distal forearm fracture in British men and women. Osteoporosis International. 2001;12:555–558
  6. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29(6):517–522
  7. Sexson SB, Lehner JT. Factors affecting hip fracture mortality. Journal of Orthopaedic Trauma. 1987;1(4):298–305
  8. Bonar SK, Tinetti ME, Speechley M, Cooney LM. Factors associated with short-versus longterm skilled nursing facility placement among community-living hip fracture patients. Journal of the American Geriatrics Society. 1990;38(10):1139–1144
  9. Pluijm SM, Tromp AM, Smit JH, et al. Consequences of vertebral deformities in older men and women. Journal of Bone and Mineral Research. 2000;15(8):1564–1572
  10. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. Journal of Bone and Mineral Research. 2000;15(7):1384–1392
  11. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fracture. Lancet. 2002;359:1761–1767
  12. European Commission . Report on Osteoporosis in the European Community: Action for Prevention. Luxembourg: European Commission; 1998;
  13. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research. 1997;12(1):24–35
  14. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. British Medical Journal. 1996;312:1254–1259
  15. Kanis J, Borgsrom F, De Lart C, et al. Assessment of fracture risk. Osteoporosis International. 2005;16:581–589
  16. Gregory L, Lowe C, Bates C, et al. National Diet and Nutrition Survey: Young People aged 4 to 18 Years. Volume 1: Report of the Diet and Nutrition Survey. London: The Stationery Office; 1998;
  17. Finch S, Doyle W, Lowe C, et al. National Diet and Nutrition Survey: People aged 65 Years or Over. Volume 1: Report of the Diet and Nutrition Survey. London: The Stationery Office; 1998;
  18. New SA, Robins SP, Campbell MK, et al. Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health. American Journal of Clinical Nutrition. 2000;71:142–151
  19. Tucker KL, Hannan MT, Chen H, et al. Potassium, magnesium, and fruit and vegetable intake are associated with greater bone mineral density in elderly men and women. American Journal of Clinical Nutrition. 1999;69:727–736
  20. Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. American Journal of Clinical Nutrition. 2000;71:2504–2512
  21. Harris SS, Dawson-Hughes B. Caffeine and bone loss in healthy menopausal women. American Journal of Clinical Nutrition. 1994;60:573–578
  22. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. British Medical Journal. 1997;315:841–846
  23. Feder G, Cryer C, Donovan S, et al. Guidelines for the prevention of falls in people over 65. British Medical Journal. 2000;321:1007–1011
  24. Van Schoor NM, Deville WL, Bouter LM, et al. Acceptance and compliance with external hip protectors: a systemic review of the literature. Osteoporosis International. 2002;13:917–924
  25. Sawka AM, Boulos P, Beattie K, et al. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporosis International. 2005;16:1461–1474
  26. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. The New England Journal of Medicine. 1990;323:878–883
  27. Reid IA, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. The New England Journal of Medicine. 1993;328:460–464
  28. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fracture in elderly women. British Medical Journal. 1994;308:1081–1082
  29. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365:1621–1628
  30. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. The New England Journal of Medicine. 2006;354:669–683
  31. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. Journal of the American Medical Association. 1941;116:2465–2474
  32. Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomized trials. BMC Musculoskeletal Disorders. 2001;2:7
  33. Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. Journal of the American Medical Association. 2001;285:2891–2897
  34. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association. 2002;288:321–333
  35. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. Journal of Bone and Mineral Research. 2006;21:817–828
  36. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. Journal of the American Medical Association. 1999;282:637–645
  37. Siris E, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) Study. Journal of Bone and Mineral Research. 2005;20:1514–1524
  38. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. The New England Journal of Medicine. 1990;322:1265–1271
  39. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. American Journal of Medicine. 1993;95:557–567
  40. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis International. 2001;12:140–151
  41. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with aledronate in women with osteoporosis: the fracture intervention trial. The Journal of Clinical Endocrinology and Metabolism. 2000;85:4118–4124
  42. Harris ST, Watts NB, Genat HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Journal of the American Medical Association. 1999;282:1344–1352
  43. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. The New England Journal of Medicine. 2001;344:333–340
  44. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 2004;19:1241–1249
  45. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. The New England Journal of Medicine. 2004;350:1189–1199
  46. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. The Journal of Clinical Endrocrinology and Metabolism. 1994;79:1595–1599
  47. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. The New England Journal of Medicine. 2002;346:653–661
  48. National Institute for Clinical Excellence . Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Health Technology Appraisal 87 London: NICE; 2005;Available at: http://www.nice.org.uk/TA087guidance
  49. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. The New England Journal of Medicine. 2004;350:459–468
  50. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2816–2822
  51. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England Journal of Medicine. 2001;344:1434–1441
  52. Chesnut CH, Silvermann S, Andriano K, et al. A randomised trial of nasal spray salmon calcitonin in postmenopausal osteoporosis: the prevent recurrence of osteoporotic fracture study. American Journal of Medicine. 2000;109:267–276

PII: S1521-6942(06)00125-2

doi: 10.1016/j.berh.2006.10.004

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 1 , Pages 109-122 , February 2007

Article Tools

* Image Usage & Resolution